Neurelis
Neurelis is a neuroscience-based company dedicated to developing life-changing treatments for neurological conditions, especially epilepsy. Founded in 2007 in San Diego, California, the company focuses on innovative therapies that empower people with neurological disorders, care partners, and healthcare providers. Their mission is to develop products, technologies, and programs that improve lives and address unmet medical needs in CNS disorders.
Industries
Nr. of Employees
medium (51-250)
Neurelis
Encinitas, California, United States, North America
Products
Intranasal diazepam rescue formulation (approved for acute seizure clusters)
An intranasal diazepam formulation developed using transmucosal absorption enhancement to enable noninvasive, rapid at‑home treatment of seizure clusters; supported by pediatric and adult clinical safety and PK studies.
Investigational intranasal small‑molecule rescue formulation for acute psychiatric agitation
Early clinical‑stage intranasal small‑molecule formulation being developed for rapid control of acute agitation related to psychiatric disorders.
Early‑stage CNS Rho kinase (ROCK) inhibitor program (investigational NCE)
Preclinical/early clinical small‑molecule Rho kinase inhibitor program acquired for treatment development in rare CNS vascular disorders, with IND plans and preclinical support from NIH SBIR funding.
Intranasal diazepam rescue formulation (approved for acute seizure clusters)
An intranasal diazepam formulation developed using transmucosal absorption enhancement to enable noninvasive, rapid at‑home treatment of seizure clusters; supported by pediatric and adult clinical safety and PK studies.
Investigational intranasal small‑molecule rescue formulation for acute psychiatric agitation
Early clinical‑stage intranasal small‑molecule formulation being developed for rapid control of acute agitation related to psychiatric disorders.
Early‑stage CNS Rho kinase (ROCK) inhibitor program (investigational NCE)
Preclinical/early clinical small‑molecule Rho kinase inhibitor program acquired for treatment development in rare CNS vascular disorders, with IND plans and preclinical support from NIH SBIR funding.
Services
Patient support and savings program
Multichannel patient support including nurse educator access, instructional materials, pharmacy connection assistance and patient assistance/savings enrollment support.
Licensing, partnership development and royalty monetization services
Business development services to structure regional licensing and commercialization agreements, pursue in‑licensing or acquisitions, and monetize royalty or receivable streams.
Medical affairs and scientific communications
Preparation and delivery of scientific content, poster and oral presentations at medical congresses, and maintenance of HCP-directed medical resources.
Patient support and savings program
Multichannel patient support including nurse educator access, instructional materials, pharmacy connection assistance and patient assistance/savings enrollment support.
Licensing, partnership development and royalty monetization services
Business development services to structure regional licensing and commercialization agreements, pursue in‑licensing or acquisitions, and monetize royalty or receivable streams.
Medical affairs and scientific communications
Preparation and delivery of scientific content, poster and oral presentations at medical congresses, and maintenance of HCP-directed medical resources.
Expertise Areas
- Transmucosal and intranasal drug delivery development
- Clinical trial management for CNS indications including pediatric studies
- Clinical pharmacokinetics and population PK modeling
- Regulatory strategy and FDA interactions (IND/NDA and designation pathways)
Key Technologies
- Transmucosal absorption enhancement
- Intranasal spray formulation and delivery systems
- Hydrogel-based stabilization and excipient systems
- Formulation approaches for peptides, proteins and small molecules